395 related articles for article (PubMed ID: 24731161)
1. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
3. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.
Goktas A; Goktas S; Atas M; Demircan S; Yurtsever Y
Cutan Ocul Toxicol; 2013 Mar; 32(1):23-6. PubMed ID: 22737998
[TBL] [Abstract][Full Text] [Related]
4. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
5. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
6. The ocular pulse amplitude at different intraocular pressure: a prospective study.
Knecht PB; Bosch MM; Michels S; Mannhardt S; Schmid U; Bosch MA; Menke MN
Acta Ophthalmol; 2011 Aug; 89(5):e466-71. PubMed ID: 21401909
[TBL] [Abstract][Full Text] [Related]
7. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
[TBL] [Abstract][Full Text] [Related]
8. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
9. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
10. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
11. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
Güler M; Capkın M; Simşek A; Bilak S; Bilgin B; Hakim Reyhan A; Fırat M
Curr Eye Res; 2014 Oct; 39(10):989-93. PubMed ID: 24588314
[TBL] [Abstract][Full Text] [Related]
12. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema.
Al-Abdullah AA; Nowilaty SR; Asghar N; Al-Kharashi AS; Ghazi NG
Retina; 2015 Mar; 35(3):440-8. PubMed ID: 25285810
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells.
Park J; Lee M
BMC Ophthalmol; 2018 Jan; 18(1):17. PubMed ID: 29368595
[TBL] [Abstract][Full Text] [Related]
14. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).
Sharei V; Höhn F; Köhler T; Hattenbach LO; Mirshahi A
Eur J Ophthalmol; 2010; 20(1):174-9. PubMed ID: 19927267
[TBL] [Abstract][Full Text] [Related]
15. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
16. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
Demirel S; Yanik O; Batioglu F; Ozmert E
Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
[TBL] [Abstract][Full Text] [Related]
18. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application.
Höhn F; Mirshahi A
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1371-5. PubMed ID: 20407785
[TBL] [Abstract][Full Text] [Related]
19. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
El Chehab H; Le Corre A; Giraud JM; Ract-Madoux G; Swalduz B; Dot C
J Fr Ophtalmol; 2012 Oct; 35(8):614-21. PubMed ID: 22832030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
